HemoCue WBC Diff

"Adherence to scheduled remote visits was moderate, with nonadherence primarily attributed to device-related complications, which may have also affected the success rate of data transfer. Overall, patients considered remote monitoring useful and feasible. The prevalence of reported adverse events was comparable to existing literature, suggesting clinical potential. This initial feasibility study highlights the potential of the DHHC."

"This study provided reliable and accurate comparative results between two types of CRP POCTs and WBC counts using the HemoCue WBC DIFF. These findings may benefit risk management for older adults at home, patients with dementia who cannot communicate, and those living in depopulated areas. Further investigations are needed to evaluate the impact of various POCTs on decision making in home nursing and their cost-effectiveness."

"This mobile laboratory represents a major advance in sudden onset disaster. Setup of the service was quick (< 24 hr) and transport to site rapid. Future deployment in fragmented health systems after sudden onset disasters with EMT2 will now allow broader diagnostic capability."

"Results from the capillary blood HemoCue WBC DIFF analyser compared well with the venous blood ADVIA 2120i analyser for determining WBC and neutrophil counts. There was a slight overall bias, with the capillary method reporting lower values for both measures. Fingerstick point-of-care analysis is suitable for monitoring blood counts in patients on clozapine, although confirmatory standard venous testing is recommended for test results falling below accepted thresholds."

Point-of-care testing for white blood cell counts significantly enhances triage in remote Australian communities by providing immediate diagnostic clarity for acute infections. The study confirms that this technology improved clinical decision-making in 41% of cases, preventing unnecessary medical retrievals while identifying high-risk patients. Ultimately, this approach optimizes resource allocation in underserved areas and offers substantial cost savings.

"Disagreement of WBC and neutrophil counts between methods appeared clinically relevant. Findings need to be verified in a larger cohort, including the use of a different type of lancet."

"The correlations between the white blood cell counts and neutrophil counts in this real-life study were good enough to diagnose children in emergency department and oncology unit settings. However, the high number of pathological flags from fingerstick samples, which made reruns necessary, limited the usefulness of the instrument."

While certain parameters like creatinine and lactate showed insufficient correlation, this study confirms that POC devices provide reliable real-time data for most hematology and biochemistry markers in critically ill patients. These devices effectively match laboratory standards for core clinical measurements, allowing for immediate bedside decision-making and significantly reducing treatment delays in intensive care settings.

The study concludes that capillary point-of-care testing is significantly less burdensome and more highly preferred by both patients and practitioners than traditional venous sampling. By reducing the physical and psychological stress of mandatory blood monitoring, this method offers a viable way to improve the patient experience and potentially increase the clinical use of clozapine.

The study validates the LeukoScope as an effective low-cost tool for point-of-care testing by comparing it to the HemoCue WBC DIFF and the clinical laboratory gold standard. Results indicate that the LeukoScope achieves comparable accuracy to both established methods in measuring white blood cell and neutrophil counts, successfully identifying the vast majority of patients with abnormal values in under five minutes.

"Our results showed that the POCTs can be used by some patients and factors influencing the patient participation included psychological and physical limitations. Both POCTs appeared to have an acceptable clinical level of accuracy."

"The HemoCue WBC DIFF provided reliable and accurate counts of total WBC, neutrophil, and lymphocyte in leukopenic samples. Until POC instruments that can perform an accurate complete blood count are available, the HemoCue WBC DIFF can be used to assist physicians in making decisions in situations of postchemotherapy leukopenia and neutropenia."

"The NPT HemoCue WBC Diff device, using a pin-prick of blood sample, is comparable to an automated Abbott Architect ci8200 laboratory analyzer when measuring PBEC levels and total cell counts in whole blood in both healthy volunteers and individuals with airways disease. This result was not affected by a self-reported history of allergy, is minimally variable and has excellent sensitivity in correctly identifying a percentage PBEC level 2%. There was excellent agreement and correlation of the PBEC measured in the NPT, with very close margins of agreement. Proportional bias at higher levels of % eosinophil counts were seen, however, if this NPT was to be used for quantification of a binary outcome threshold of 2% to make treatment decisions regarding corticosteroids12 then this proportional bias at higher levels of PBEC is not clinically significant. Repeated sampling, in patients with COPD, was also found to be excellent. We suggest that this NPT can be used to measure eosinophil counts in patients with asthma and COPD."

"The point-of-care device can be used to screen for leukocyte and neutrophil counts. Because of the relatively high measurement uncertainty and poor correlation with venous samples, we recommend to repeat the measurement with a venous sample if cell counts are in the lower reference range. In case of clozapine therapy, neutropenia can probably be excluded if high neutrophil counts are found and patients can continue their therapy."